# US 2013/0273532 A1 · Upregulation of rack-1 in melanoma and its use as a marker

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0273532 A1
- Document ID: US20130273532A1
- Status: Published application
- Kind: A1
- Application number: 13/730,243
- Filed: 2012-12-28
- Published: 2013-10-17
- Earliest claimed: 2007-07-31
- Assignees: Institut Pasteur; Centre National De La Recherche Scientifique; Institut National de la Recherche Agronomique (INRA); Ecole Nationale Veterinaire D'Alfort; Institut Curie
- Applicants: Institut Pasteur; Centre National de la Recherche Scientifique; Institut National de la Recherche Agronomique (INRA); Ecole Nationale Veterinaire D'Alfort; Institut Curie
- Inventors: Jean-Jacques Panthier; Giorgia Egidy; Xavier Sastre-Garau; Florence Bernex
- Web page: https://patentgrep.com/patent/US20130273532A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5751: of the skin, e.g. melanoma
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2333/9121: with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A method for detecting a melanocyte tumor in a human patient comprising:
a) providing a biopsy comprising melanocytes from a human patient; and
b) detecting expression of RACK-1 mRNA in the melanocytes;
wherein overexpression of RACK-1 mRNA in the melanocytes is indicative of a melanocyte tumor.

### Claim 30 (depends on 29)

The method of claim 29, wherein high expression of RACK-1 mRNA is detected in the melanocytes indicating the presence of a melanoma in the biopsy.

### Claim 31 (depends on 29)

The method of claim 29, wherein low expression of RACK-1 mRNA is detected in the melanocytes indicating the presence of a benign nevi in the biopsy.

### Claim 32 (depends on 29)

The method of claim 29, wherein the melanocytes are epidermal melanocytes.

### Claim 33 (depends on 29)

The method of claim 29, wherein RACK-1 mRNA in the melanocytes is detected by in situ hybridization.

### Claim 34 (depends on 29)

The method of claim 29, wherein the biopsy is a skin biopsy.

### Claim 35 (depends on 29)

The method of claim 29, wherein the biopsy is an eye biopsy.

### Claim 36 (depends on 29)

The method of claim 29, further comprising detecting melanocytes with an antibody.

### Claim 37 (depends on 36)

The method of claim 36, wherein the melanocytes are detected by an in situ immunoassay.

### Claim 38 (depends on 36)

The method of claim 36, wherein the melanocytes are detected with a monoclonal antibody.

### Claim 39 (depends on 36)

The method of claim 36, wherein the antibody for detecting melanocytes is against the microphthalmia transciption factor MITF, the dopachrome tautomerase DCT, the tyrosinase TYR, or the tyrosinase-related protein 1 TRP1.

### Claim 40

A method for detecting a melanocyte tumor in a horse or dog comprising:
a) providing a biopsy comprising melanocytes from a horse or dog; and
b) detecting expression of RACK-1 mRNA in the melanocytes;
wherein overexpression of RACK-1 mRNA in the melanocytes is indicative of a melanocyte tumor.

### Claim 41 (depends on 40)

The method of claim 40, wherein the melanocyte tumor is a melanoma.

### Claim 42 (depends on 40)

The method of claim 40, wherein the melanocyte tumor is benign.

### Claim 43 (depends on 40)

The method of claim 40, wherein the melanocytes are epidermal melanocytes.

### Claim 44 (depends on 40)

The method of claim 40, wherein RACK-1 mRNA in the melanocytes is detected by in situ hybridization.

### Claim 45 (depends on 40)

The method of claim 40, wherein the biopsy is a skin biopsy.

### Claim 46 (depends on 40)

The method of claim 40, wherein the biopsy is an eye biopsy.

### Claim 47 (depends on 40)

The method of claim 40, further comprising detecting melanocytes with an antibody.

### Claim 48 (depends on 47)

The method of claim 47, wherein the melanocytes are detected by an in situ immunoassay.

### Claim 49 (depends on 47)

The method of claim 47, wherein the melanocytes are detected with a monoclonal antibody.

### Claim 50 (depends on 47)

The method of claim 47, wherein the antibody for detecting melanocytes is against the microphthalmia transciption factor MITF, the dopachrome tautomerase DCT, the tyrosinase TYR, or the tyrosinase-related protein 1 TRP1.

### Claim 51 (depends on 40)

The method of claim 40, wherein a biopsy comprising melanocytes from a horse is provided.

### Claim 52 (depends on 40)

The method of claim 40, wherein a biopsy comprising melanocytes from a dog is provided.
